Eric D. Hawkins

TL;DR: It is concluded that FGF-21, which was discovered to be a potent regulator of glucose uptake in mouse 3T3-L1 and primary human adipocytes, exhibits the therapeutic characteristics necessary for an effective treatment of diabetes.

TL;DR: It is demonstrated that the sphingolipid ceramide is a common molecular intermediate linking several different pathological metabolic stresses to the induction of insulin resistance, and enzymes required for ceramide synthesis are identified as therapeutic targets for combating insulin resistance caused by nutrient excess or glucocorticoid therapy.

TL;DR: Results provide the first evidence that actin cytoskeletal mechanics are an essential feature of the glucose transport process in intact skeletal muscle and support a distal actin-based role for N-WASP in insulin action in vivo.

TL;DR: A series of potent and selective GSK3 inhibitors are discovered, 7-12 show oral activity in an in vivo model of type II diabetes, and 9 and 12 have desirable PK properties.

TL;DR: Immunohistological studies provided direct evidence that the enzyme is expressed not only in the villi, but also in the crypt regions of the small intestine, which suggests that MGAT2 expression occurs prior to the maturation of enterocytes.